Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abraxis Bioscience, Inc.

http://www.abraxisbio.com

Latest From Abraxis Bioscience, Inc.

Finance Watch: Another VC Mega-Round As Flare Raises $123m Series B

Private Company Edition: Flare Therapeutics, targeting transcription factors to discover precision medicines, had big pharma backing for its second venture capital financing. Also, Mediar closed a $10m series A round, Switch launched with $52m and EpiBiologics raised a $50m series A round.

Financing Innovation

Acesion Seeks Partner For First-In-Class AF Program Following Phase II Success

Having reached proof-of-concept for its first-in-class SK ion channel inhibitor for atrial fibrillation, the Danish firm is on the hunt for a licensee as it moves its attention to its preclinical program for sinus rhythm maintenance.

Clinical Trials Cardiovascular

Chinese Biotechs Ascend Deal-Making By Partnering Up Claudin 18.2 Agents

The recent partnerships on Claudin 18.2-targeting agents between Chinese biotechs and big pharma have brought China innovation to a new phase that Chinese firms can be proud of, an executive from Keymed Biosciences, one of the Chinese biotechs involved in such deals, tells Scrip in an interview.

China Deals

Akeso's Xia Looks Beyond Summit Deal To Independent Global Development, Sales

Last December, China's Akeso struck a major agreement worth up to $5bn with Summit Therapeutics, which set a new record in terms of total deal value for a single asset in the Chinese biopharma sector. Akeso founder and CEO Michelle Xia is now planning to pursue a more independent path in taking the firm global.

China Deals
See All

Company Information

  • Other Names / Subsidiaries
    • Shimoda Biotech Ltd.
UsernamePublicRestriction

Register